Next Article in Journal
ETF-QO Mutants Uncoupled Fatty Acid β-Oxidation and Mitochondrial Bioenergetics Leading to Lipid Pathology
Next Article in Special Issue
Mesenchymal Stem Cells-derived Exosomes: A New Possible Therapeutic Strategy for Parkinson’s Disease?
Previous Article in Journal
Control of the Antitumor Immune Response by Cancer Metabolism
Previous Article in Special Issue
Impairment of Motor Function Correlates with Neurometabolite and Brain Iron Alterations in Parkinson’s Disease
Open AccessFeature PaperReview

Novel Immunotherapeutic Approaches to Target Alpha-Synuclein and Related Neuroinflammation in Parkinson’s Disease

Department of Neurology, St. Josef-Hospital, Ruhr-University Bochum, 44791 Bochum, Germany
Department of Neurology, St. Josef- Hospital, Katholische Kliniken Ruhrhalbinsel, Contilia Gruppe, 45257 Essen, Germany
Department of Neurology, University Medical Center, 37075 Goettingen, Germany
Neurodegeneration Research, Protein Research Unit Ruhr (PURE), Ruhr University Bochum, 44801 Bochum, Germany
Author to whom correspondence should be addressed.
Cells 2019, 8(2), 105;
Received: 31 December 2018 / Revised: 23 January 2019 / Accepted: 29 January 2019 / Published: 31 January 2019
(This article belongs to the Special Issue The Molecular and Cellular Basis for Parkinson's Disease)
The etiology of Parkinson’s disease (PD) is significantly influenced by disease-causing changes in the protein alpha-Synuclein (aSyn). It can trigger and promote intracellular stress and thereby impair the function of dopaminergic neurons. However, these damage mechanisms do not only extend to neuronal cells, but also affect most glial cell populations, such as astroglia and microglia, but also T lymphocytes, which can no longer maintain the homeostatic CNS milieu because they produce neuroinflammatory responses to aSyn pathology. Through precise neuropathological examination, molecular characterization of biomaterials, and the use of PET technology, it has been clearly demonstrated that neuroinflammation is involved in human PD. In this review, we provide an in-depth overview of the pathomechanisms that aSyn elicits in models of disease and focus on the affected glial cell and lymphocyte populations and their interaction with pathogenic aSyn species. The interplay between aSyn and glial cells is analyzed both in the basic research setting and in the context of human neuropathology. Ultimately, a strong rationale builds up to therapeutically reduce the burden of pathological aSyn in the CNS. The current antibody-based approaches to lower the amount of aSyn and thereby alleviate neuroinflammatory responses is finally discussed as novel therapeutic strategies for PD. View Full-Text
Keywords: Parkinson’s disease; neuroinflammation; alpha-Synuclein; immunotherapy Parkinson’s disease; neuroinflammation; alpha-Synuclein; immunotherapy
MDPI and ACS Style

Zella, M.A.S.; Metzdorf, J.; Ostendorf, F.; Maass, F.; Muhlack, S.; Gold, R.; Haghikia, A.; Tönges, L. Novel Immunotherapeutic Approaches to Target Alpha-Synuclein and Related Neuroinflammation in Parkinson’s Disease. Cells 2019, 8, 105.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

Search more from Scilit
Back to TopTop